mBC, also known as "advanced breast cancer," is cancer that starts in the breast tissue and then spreads to other parts of the body.

There are 4 main breast cancer subtypes based on the presence or absence of hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2/neu).*

• HR+/HER2/neu- or “Luminal A” (67%)
• HR-/HER2/neu- or “TNBC” (10%)
• HR+/HER2/neu+ or “Luminal B” (10%)
• HR-/HER2/neu+ or “HER2/neu-enriched” (4%)
• Unknown (8%)

*Based on data from cases in 2012-2016.

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that accounts for about 10% of all breast cancers. TNBC does not have estrogen or progesterone receptors (hormone-negative), is HER2/neu-negative, and typically spreads and grows faster than other breast cancers.

mBC accounts for about 6% of new cases of breast cancer and affects about one-third of all women with breast cancer.^† In 2020, there were almost 280,000 estimated new cases of breast cancer diagnosed.

^†Based on data from cases in 2012-2016.

Let your health care team know when you experience side effects. Keep track of your side effects and what affects them. This information may be helpful to your health care team when making decisions regarding your treatment.

For more information on side effects, click here.